As of May 1, 2025, our over 5,000 healthcare partners throughout the United States have dispensed over 2,000,000 units of our market leading Tolcylen® products. Additionally, two new products have been cleared for an early 4th quarter launch this year. The new products are expected to drive additional revenue growth from existing and new market specialties.
Marlinz Pharma Surpasses 2,000,000 Units of Tolcylen® Products Dispensed and Announces Further Expansion of Our Drug/Cosmetic Offerings.
